B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund Has $1.08 Million Holdings in Eli Lilly And Co (LLY)

B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 55.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,604 shares of the company’s stock after selling 15,844 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Eli Lilly And Co were worth $1,075,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of LLY. Victory Capital Management Inc. lifted its holdings in Eli Lilly And Co by 3.8% during the first quarter. Victory Capital Management Inc. now owns 19,693 shares of the company’s stock worth $1,524,000 after buying an additional 727 shares during the period. Chicago Equity Partners LLC lifted its holdings in shares of Eli Lilly And Co by 37.8% during the 1st quarter. Chicago Equity Partners LLC now owns 18,105 shares of the company’s stock valued at $1,401,000 after purchasing an additional 4,965 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Eli Lilly And Co by 147.8% during the 1st quarter. Thrivent Financial for Lutherans now owns 346,594 shares of the company’s stock valued at $26,817,000 after purchasing an additional 206,748 shares during the last quarter. Timber Hill LLC purchased a new stake in shares of Eli Lilly And Co during the 1st quarter valued at $258,000. Finally, Intact Investment Management Inc. purchased a new stake in shares of Eli Lilly And Co during the 1st quarter valued at $217,000. Institutional investors own 76.55% of the company’s stock.

Several analysts have recently commented on LLY shares. BMO Capital Markets increased their price objective on Eli Lilly And Co from $78.00 to $80.00 and gave the company a “$89.43” rating in a report on Thursday, July 19th. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b” rating in a report on Friday, June 29th. JPMorgan Chase & Co. set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, June 11th. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Wednesday, May 30th. Finally, Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, July 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and a consensus price target of $100.69.

Shares of LLY stock opened at $106.58 on Friday. The firm has a market capitalization of $113.46 billion, a P/E ratio of 24.84, a PEG ratio of 1.76 and a beta of 0.28. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $107.84.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. The company had revenue of $6.36 billion during the quarter, compared to analyst estimates of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $1.11 EPS. analysts forecast that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, September 10th. Investors of record on Wednesday, August 15th were paid a $0.5625 dividend. The ex-dividend date of this dividend was Tuesday, August 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.11%. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $106.76, for a total value of $19,216,800.00. Following the completion of the transaction, the insider now owns 119,832,753 shares in the company, valued at approximately $12,793,344,710.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Eli & Co Lilly sold 4,531 shares of the firm’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $14.33, for a total value of $64,929.23. Following the completion of the transaction, the insider now owns 3,934,137 shares of the company’s stock, valued at approximately $56,376,183.21. The disclosure for this sale can be found here. Insiders sold a total of 1,675,011 shares of company stock valued at $166,959,769 in the last 90 days. 0.11% of the stock is currently owned by company insiders.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What is a closed-end mutual fund (CEF)?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply